the results of sample size based on PowerTOST [Software]

posted by libaiyi – China, 2018-07-27 07:34 (2072 d 06:22 ago) – Posting: # 19107
Views: 6,345

(edited by libaiyi on 2018-07-27 07:47)

Hi,

I have a naive question about the results of sample size based on SampleN.TOST, sampleN.NTIDFDA, sampleN.HVNTID etc.

For example,
sampleN.RSABE(CV=0.3)

++++++++ Reference scaled ABE crit. +++++++++
           Sample size estimation
---------------------------------------------
Study design:  2x3x3 (partial replicate)
log-transformed data (multiplicative model)
1e+05 studies for each step simulated.

alpha  = 0.05, target power = 0.8
CVw(T) = 0.3; CVw(R) = 0.3
True ratio = 0.9
ABE limits / PE constraints = 0.8 ... 1.25
FDA regulatory settings
- CVswitch            = 0.3
- regulatory constant = 0.8925742
- pe constraint applied


Sample size search
 n     power
39   0.75781
42   0.78122
45   0.80344



I want to know if the target power is 0.8, the sample size is 45 for each group or for whole study.



The other question,
when we apply power.TOST, the sample size we need to fill in should be number in each group or whole study.


Third question,:-):-):-):-)
I am confused about the relationship between power and period. Are the power calculation method applied in 2*2, 3*3 and 2*4 designs the same?:-D For example, if I have the result like this of the study design as T-S-R, could I use the same method to calculate power separately for T-R and S-R? Should I get two power as the result? And, what about parallel design?

[image]

Thanks in advance! :flower:

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
112 visitors (0 registered, 112 guests [including 4 identified bots]).
Forum time: 12:56 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5